Is SMMT or GRAL more profitable?

Summit Therapeutics has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% GRAIL -236.95% -15.88% -14.02%

Does the media refer more to SMMT or GRAL?

In the previous week, Summit Therapeutics had 10 more articles in the media than GRAIL. MarketBeat recorded 20 mentions for Summit Therapeutics and 10 mentions for GRAIL. GRAIL's average media sentiment score of 0.60 beat Summit Therapeutics' score of 0.42 indicating that GRAIL is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral GRAIL 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, BBIO or GRAL?

GRAIL has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BridgeBio Pharma $502.08M 26.16 -$724.93M -$3.57 N/A GRAIL $147.17M 42.68 -$408.35M -$9.75 N/A

Is BBIO or GRAL more profitable?

BridgeBio Pharma has a net margin of -97.03% compared to GRAIL's net margin of -236.95%. BridgeBio Pharma's return on equity of 0.00% beat GRAIL's return on equity. Company Net Margins Return on Equity Return on Assets BridgeBio Pharma -97.03% N/A -61.19% GRAIL -236.95% -15.88% -14.02%

Does the media favor BBIO or GRAL?

In the previous week, GRAIL had 6 more articles in the media than BridgeBio Pharma. MarketBeat recorded 10 mentions for GRAIL and 4 mentions for BridgeBio Pharma. GRAIL's average media sentiment score of 0.60 beat BridgeBio Pharma's score of 0.51 indicating that GRAIL is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRAIL 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, GRAL or HALO?

Halozyme Therapeutics has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $147.17M 42.68 -$408.35M -$9.75 N/A Halozyme Therapeutics $1.40B 8.88 $316.89M $3.35 32.62

Does the media favor GRAL or HALO?

In the previous week, GRAIL had 3 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 10 mentions for GRAIL and 7 mentions for Halozyme Therapeutics. GRAIL's average media sentiment score of 0.60 beat Halozyme Therapeutics' score of 0.19 indicating that GRAIL is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, BMRN or GRAL?

BioMarin Pharmaceutical has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioMarin Pharmaceutical $3.22B 3.46 $348.90M $0.37 155.83 GRAIL $147.17M 42.68 -$408.35M -$9.75 N/A

Does the media favor BMRN or GRAL?

In the previous week, BioMarin Pharmaceutical had 2 more articles in the media than GRAIL. MarketBeat recorded 12 mentions for BioMarin Pharmaceutical and 10 mentions for GRAIL. BioMarin Pharmaceutical's average media sentiment score of 0.68 beat GRAIL's score of 0.60 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRAIL 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, GRAL or MDGL?

Madrigal Pharmaceuticals has higher revenue and earnings than GRAIL. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $147.17M 42.68 -$408.35M -$9.75 N/A Madrigal Pharmaceuticals $958.40M 11.99 -$288.28M -$12.89 N/A

Does the media favor GRAL or MDGL?

In the previous week, GRAIL had 8 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 10 mentions for GRAIL and 2 mentions for Madrigal Pharmaceuticals. GRAIL's average media sentiment score of 0.60 beat Madrigal Pharmaceuticals' score of 0.57 indicating that GRAIL is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

GRAIL (GRAL) Competitors

$143.26 +10.70 (+8.07%)

Closing price 04:00 PM Eastern

Extended Trading

$143.76 +0.50 (+0.35%)

As of 07:13 PM Eastern

Compare

GRAL vs. SMMT, BBIO, HALO, BMRN, and MDGL

Should you buy GRAIL stock or one of its competitors? GRAIL's main competitors and comparable companies include Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), Halozyme Therapeutics (HALO), BioMarin Pharmaceutical (BMRN), and Madrigal Pharmaceuticals (MDGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does GRAIL compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

4.6% of Summit Therapeutics shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Comparatively, 1.8% of GRAIL shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

GRAIL has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
GRAIL	$147.17M	42.68	-$408.35M	-$9.75	N/A

In the previous week, Summit Therapeutics had 10 more articles in the media than GRAIL. MarketBeat recorded 20 mentions for Summit Therapeutics and 10 mentions for GRAIL. GRAIL's average media sentiment score of 0.60 beat Summit Therapeutics' score of 0.42 indicating that GRAIL is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
GRAIL	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics has a beta of -1.51, suggesting that its stock price is 251% less volatile than the broader market. Comparatively, GRAIL has a beta of 2.81, suggesting that its stock price is 181% more volatile than the broader market.

Summit Therapeutics has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
GRAIL	-236.95%	-15.88%	-14.02%

Summit Therapeutics currently has a consensus price target of $28.61, suggesting a potential upside of 70.00%. GRAIL has a consensus price target of $102.70, suggesting a potential downside of 26.97%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Summit Therapeutics is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53
GRAIL	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Summit Therapeutics beats GRAIL on 9 of the 16 factors compared between the two stocks.

How does GRAIL compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, GRAIL has a beta of 2.81, indicating that its share price is 181% more volatile than the broader market.

BridgeBio Pharma currently has a consensus target price of $102.61, indicating a potential upside of 52.72%. GRAIL has a consensus target price of $102.70, indicating a potential downside of 26.97%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe BridgeBio Pharma is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
GRAIL	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

BridgeBio Pharma has a net margin of -97.03% compared to GRAIL's net margin of -236.95%. BridgeBio Pharma's return on equity of 0.00% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
GRAIL	-236.95%	-15.88%	-14.02%

GRAIL has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.16	-$724.93M	-$3.57	N/A
GRAIL	$147.17M	42.68	-$408.35M	-$9.75	N/A

99.9% of BridgeBio Pharma shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 1.8% of GRAIL shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, GRAIL had 6 more articles in the media than BridgeBio Pharma. MarketBeat recorded 10 mentions for GRAIL and 4 mentions for BridgeBio Pharma. GRAIL's average media sentiment score of 0.60 beat BridgeBio Pharma's score of 0.51 indicating that GRAIL is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GRAIL	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BridgeBio Pharma beats GRAIL on 9 of the 16 factors compared between the two stocks.

How does GRAIL compare to Halozyme Therapeutics?

GRAIL (NASDAQ:GRAL) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Halozyme Therapeutics has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	42.68	-$408.35M	-$9.75	N/A
Halozyme Therapeutics	$1.40B	8.88	$316.89M	$3.35	32.62

In the previous week, GRAIL had 3 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 10 mentions for GRAIL and 7 mentions for Halozyme Therapeutics. GRAIL's average media sentiment score of 0.60 beat Halozyme Therapeutics' score of 0.19 indicating that GRAIL is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.8% of Halozyme Therapeutics shares are held by institutional investors. 1.8% of GRAIL shares are held by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

GRAIL currently has a consensus target price of $102.70, indicating a potential downside of 26.97%. Halozyme Therapeutics has a consensus target price of $91.20, indicating a potential downside of 16.54%. Given Halozyme Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Halozyme Therapeutics is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

GRAIL has a beta of 2.81, suggesting that its share price is 181% more volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

Halozyme Therapeutics has a net margin of 24.86% compared to GRAIL's net margin of -236.95%. Halozyme Therapeutics' return on equity of 260.98% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-236.95%	-15.88%	-14.02%
Halozyme Therapeutics	24.86%	260.98%	23.91%

Summary

Halozyme Therapeutics beats GRAIL on 12 of the 16 factors compared between the two stocks.

How does GRAIL compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

BioMarin Pharmaceutical has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, GRAIL has a beta of 2.81, suggesting that its stock price is 181% more volatile than the broader market.

In the previous week, BioMarin Pharmaceutical had 2 more articles in the media than GRAIL. MarketBeat recorded 12 mentions for BioMarin Pharmaceutical and 10 mentions for GRAIL. BioMarin Pharmaceutical's average media sentiment score of 0.68 beat GRAIL's score of 0.60 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	4 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GRAIL	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical presently has a consensus price target of $89.17, indicating a potential upside of 54.67%. GRAIL has a consensus price target of $102.70, indicating a potential downside of 26.97%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, equities research analysts clearly believe BioMarin Pharmaceutical is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.67
GRAIL	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

BioMarin Pharmaceutical has a net margin of 2.14% compared to GRAIL's net margin of -236.95%. BioMarin Pharmaceutical's return on equity of 5.32% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
GRAIL	-236.95%	-15.88%	-14.02%

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Comparatively, 1.8% of GRAIL shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BioMarin Pharmaceutical has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.46	$348.90M	$0.37	155.83
GRAIL	$147.17M	42.68	-$408.35M	-$9.75	N/A

Summary

BioMarin Pharmaceutical beats GRAIL on 14 of the 17 factors compared between the two stocks.

How does GRAIL compare to Madrigal Pharmaceuticals?

GRAIL (NASDAQ:GRAL) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

GRAIL has a beta of 2.81, meaning that its share price is 181% more volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, meaning that its share price is 204% less volatile than the broader market.

Madrigal Pharmaceuticals has higher revenue and earnings than GRAIL. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	42.68	-$408.35M	-$9.75	N/A
Madrigal Pharmaceuticals	$958.40M	11.99	-$288.28M	-$12.89	N/A

In the previous week, GRAIL had 8 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 10 mentions for GRAIL and 2 mentions for Madrigal Pharmaceuticals. GRAIL's average media sentiment score of 0.60 beat Madrigal Pharmaceuticals' score of 0.57 indicating that GRAIL is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 1.8% of GRAIL shares are held by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Madrigal Pharmaceuticals has a net margin of -25.32% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-236.95%	-15.88%	-14.02%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

GRAIL presently has a consensus price target of $102.70, indicating a potential downside of 26.97%. Madrigal Pharmaceuticals has a consensus price target of $710.20, indicating a potential upside of 42.77%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

GRAIL and Madrigal Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get GRAIL News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRAL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRAL vs. The Competition

Export

Metric	GRAIL	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.40B	$3.84B	$7.09B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-14.69	12.99	274.61	26.05
Price / Sales	43.48	1,288.54	600.52	89.39
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	2.17	16.63	10.92	6.31
Net Income	-$408.35M	-$22.67M	$3.50B	$361.43M
7 Day Performance	12.90%	-3.05%	-2.11%	-1.67%
1 Month Performance	77.83%	-10.75%	-6.34%	-3.94%
1 Year Performance	121.32%	21.11%	8.81%	2.77%

GRAIL Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRAL GRAIL	1.0466 of 5 stars	$143.26 +8.1%	$102.70 -28.3%	+113.6%	$6.40B	$147.17M	N/A	910	Analyst Forecast Gap Up
SMMT Summit Therapeutics	2.8789 of 5 stars	$16.90 -5.3%	$25.91 +53.3%	-18.5%	$14.24B	N/A	N/A	265	Analyst Forecast
BBIO BridgeBio Pharma	3.097 of 5 stars	$66.58 0.0%	$102.61 +54.1%	+25.1%	$13.02B	$502.08M	N/A	839
HALO Halozyme Therapeutics	2.746 of 5 stars	$111.45 -0.9%	$91.20 -18.2%	+42.7%	$12.76B	$1.66B	33.27	423	Insider Trade
BMRN BioMarin Pharmaceutical	4.4634 of 5 stars	$64.06 +0.2%	$89.17 +39.2%	+6.5%	$12.38B	$3.22B	173.14	3,221	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRAL) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GRAIL (GRAL) Competitors

GRAL vs. SMMT, BBIO, HALO, BMRN, and MDGL

How does GRAIL compare to Summit Therapeutics?

Summary

How does GRAIL compare to BridgeBio Pharma?

Summary

How does GRAIL compare to Halozyme Therapeutics?

Summary

How does GRAIL compare to BioMarin Pharmaceutical?

Summary

How does GRAIL compare to Madrigal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAL vs. The Competition

GRAIL Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GRAIL (GRAL) Competitors

GRAL vs. SMMT, BBIO, HALO, BMRN, and MDGL

How does GRAIL compare to Summit Therapeutics?

Do insiders & institutionals hold more shares of SMMT or GRAL?

Which has higher valuation and earnings, SMMT or GRAL?

Does the media refer more to SMMT or GRAL?

Which has more volatility and risk, SMMT or GRAL?

Is SMMT or GRAL more profitable?

Do analysts rate SMMT or GRAL?

Summary

How does GRAIL compare to BridgeBio Pharma?

Which has more risk & volatility, BBIO or GRAL?

Do analysts rate BBIO or GRAL?

Is BBIO or GRAL more profitable?

Which has higher valuation and earnings, BBIO or GRAL?

Do insiders and institutionals have more ownership in BBIO or GRAL?

Does the media favor BBIO or GRAL?

Summary

How does GRAIL compare to Halozyme Therapeutics?

Which has preferable valuation and earnings, GRAL or HALO?

Does the media favor GRAL or HALO?

Do institutionals and insiders have more ownership in GRAL or HALO?

Do analysts prefer GRAL or HALO?

Which has more volatility & risk, GRAL or HALO?

Is GRAL or HALO more profitable?

Summary

How does GRAIL compare to BioMarin Pharmaceutical?

Which has more volatility and risk, BMRN or GRAL?

Does the media favor BMRN or GRAL?

Do analysts prefer BMRN or GRAL?

Is BMRN or GRAL more profitable?

Do institutionals & insiders have more ownership in BMRN or GRAL?

Which has stronger earnings & valuation, BMRN or GRAL?

Summary

How does GRAIL compare to Madrigal Pharmaceuticals?

Which has more risk and volatility, GRAL or MDGL?

Which has stronger valuation and earnings, GRAL or MDGL?

Does the media favor GRAL or MDGL?

Do institutionals and insiders have more ownership in GRAL or MDGL?

Is GRAL or MDGL more profitable?

Do analysts recommend GRAL or MDGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAL vs. The Competition

GRAIL Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools